2. Search Result
Search Result
Results for "

antiviral efficacy

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W013441
    2',3'-Dideoxyadenosine
    1 Publications Verification

    		 HIV Infection
    2',3'-Dideoxyadenosine is an inhibitor of HIV replication . Antiretroviral activity . Antiviral efficacy .
    2',3'-Dideoxyadenosine
  • HY-136782
    ST-148 maleate

    		Flavivirus Dengue Virus Infection
    ST-148 maleate is a potent and orally active DENV inhibitor. ST-148 maleate shows antiviral efficacy and low cell toxicity. ST-148 alters the interaction between lipid droplets and the C protein, thereby inhibiting viral replication. .
    ST-148 maleate
  • HY-100176
    PF-4878691

    3M-852A

    		 Toll-like Receptor (TLR) Apoptosis TNF Receptor HCV Interleukin Related Infection Inflammation/Immunology Cancer
    PF-4878691 (3M-852A) is an orally active TLR7 agonist. PF-4878691 has the innate immune response activity, antiviral efficacy against HCV, and can be used for the research of cancer .
    PF-4878691
  • HY-133894
    Bofutrelvir

    FB2001

    		 SARS-CoV Infection
    Bofutrelvir (FB2001) is a SARS-CoV-2 main protease M pro inhibitor with an IC50 value of 53 nM and an EC50 value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC50 values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir (HY-104077) .
    Bofutrelvir
  • HY-170922
    SARS-CoV-2-IN-110

    		SARS-CoV Infection
    SARS-CoV-2-IN-110 (compound Bb1) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-110 exhibits antiviral efficacy against SARS-CoV-2 with an EC50 of 1.10 μM and significantly lower toxicity compared to Lapatinib (HY-50898). SARS-CoV-2-IN-110 inhibits SARS-CoV-2 with a CC50 of > 100 μM, with a selectivity index (SI) of >91 .
    SARS-CoV-2-IN-110
  • HY-N15215
    Antiviral agent 64

    		Enterovirus Influenza Virus RSV HSV Infection Cancer
    Antiviral agent 64 (Compound 12) is a diarylheptanoid that can be isolated from Alpinia officinarum. Antiviral agent 64 exhibits cytotoxicity in human neuroblastoma cell IMR-32 with an IC50 of 0.23 μM. Antiviral agent 64 exhibits antiviral efficacy, that inhibits RSV, poliovirus, measles virus, HSV-1, and influenza virus H1N1, with EC50 of 13.3, 3.7, 6.3, 5.7, and <10 μg/mL, respectively .
    Antiviral agent 64
  • HY-P10804
    PIH

    		SARS-CoV Infection
    PIH is an antiviral peptide that effectively inhibits the HR1/HR2-mediated membrane fusion between MERS-CoV and host cells, with an IC50 of 1.171 μM. By forming a complex with gold nanorods (AuNRs), the antiviral efficacy of PIH can be further enhanced by 10-fold .
    PIH
  • HY-W013441R
    2',3'-Dideoxyadenosine (Standard)

    		HIV Infection
    2',3'-Dideoxyadenosine (Standard) is the analytical standard of 2',3'-Dideoxyadenosine. This product is intended for research and analytical applications. 2',3'-Dideoxyadenosine is an inhibitor of HIV replication . Antiretroviral activity . Antiviral efficacy .
    2',3'-Dideoxyadenosine (Standard)
  • HY-P99710
    Lomtegovimab

    BI 767551; DZIF-10c

    		 SARS-CoV Infection
    Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
    Lomtegovimab
  • HY-W070093
    KKJ00626

    		HBV Infection
    KKJ00626 is an inhibitor for Hepatitis B virus (HBV) with an IC50 of 0.12~0.23 μM. KKJ00626 inhibits the interaction between HBV core protein and the surface protein PreS region, prevents the maturation and secretion of HBV particles, and exhibits antiviral efficacy .
    KKJ00626
  • HY-14818B
    Laninamivir TFA

    R 125489 TFA

    		 Influenza Virus Infection
    Laninamivir TFA (R 125489 TFA) is an antiviral compound with inhibitory and prophylactic activity against influenza A and B viruses. Laninamivir TFA is a long-acting neuraminidase inhibitor administered by nasal inhalation. Laninamivir TFA has shown good safety and efficacy in the inhibition of influenza viruses .
    Laninamivir TFA
  • HY-107338
    Denotivir

    Vratizolin; Wratizolin

    		 HSV Interleukin Related Infection Inflammation/Immunology Cancer
    Denotivir (Vratizolin) is an orally active antiviral agent for herpes simplex virus (HSV) and varicella-zoster virus (VZV). Denotivir inhibits the proliferation of various cancer cells, and exhibits anti-leukemic activity. Denotivir inhibits the generation of TNF-α, IL-1 and IL-6, exhibits immunosuppressive efficacy .
    Denotivir
  • HY-167919
    1-(1-Adamantyl)-3-butyl-2-thiourea

    		Drug Derivative Infection
    1-(1-Adamantyl)-3-butyl-2-thiourea is a compound with antiviral activity, demonstrating efficacy against various viral pathogens; 1-(1-Adamantyl)-3-butyl-2-thiourea serves as a potential therapeutic agent in the treatment of viral infections.
    1-(1-Adamantyl)-3-butyl-2-thiourea
  • HY-153810
    Mosnodenvir

    JNJ-1802

    		 Virus Protease Flavivirus Dengue Virus Infection
    Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    Mosnodenvir
  • HY-156346
    HCoV-OC43-IN-1

    		SARS-CoV Infection
    HCoV-OC43-IN-1 (Compound IV-16) is a coronavirus HCoV-OC43 inhibitor. HCoV-OC43-IN-1 has antiviral efficacy (EC50: 90 nM). HCoV-OC43-IN-1 inhibits the mRNA level and expression of viral nucleocapsid protein (NP) .
    HCoV-OC43-IN-1
  • HY-121763
    SCH-43478

    		HSV Infection
    SCH-43478 is a non-nucleoside antiviral agent. SCH-43478 shows potent and selective activity against herpes simplex virus type 2 (HSV-2) with an IC50 of 1.8 μg/mL using Vero cells. SCH-43478 demonstrates significant efficacy in the guinea pig genital model of HSV infection .
    SCH-43478
  • HY-107468
    PL-100

    		HIV Protease Infection Inflammation/Immunology
    PL-100 is a potent HIV-1 protease inhibitor with a Ki of 36 pM and an EC50 of 16 nM. PL-100 inhibits viral replication by suppressing HIV-1 protease activity and demonstrates excellent antiviral efficacy against drug-resistant HIV strains. PL-100 can be used in research on drug-resistant HIV disease .
    PL-100
  • HY-170395
    GHP-88309

    		RSV DNA/RNA Synthesis Infection
    GHP-88309 is a broad-spectrum, orally active antiviral agent targeting paramyxoviruses, that targets the viral polymerase, interupts the viral RNA synthesis, and inhibits respiratory syncytial virus (RSV), measles virus (MeV), and canine distemper virus (CDV) with EC50 of 0.06-1.2 μM. GHP-88309 exhibits anti-infectious efficacy in mouse models .
    GHP-88309
  • HY-132306
    CCF0058981
    1 Publications Verification

    CCF981

    		 SARS-CoV Virus Protease Infection
    CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CL pro (SC2) inhibitor with an IC50 of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CL pro) with an IC50 of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research .
    CCF0058981
  • HY-19925
    AIC-292

    		HIV Infection
    AIC-292 is a potent and selective inhibitor of HIV-1 nonnucleoside reverse transcriptase. AIC-292 inhibits wild-type HIV-1 laboratory strains at low nanomolar concentrations. AIC-292 displays potent antiviral in vivo efficacy in a mouse xenograft model. AIC-292 has the potential for the research of HIV-1 infection .
    AIC-292
  • HY-N6693
    Valinomycin
    5 Publications Verification

    NSC 122023

    		 Apoptosis Antibiotic Autophagy Fungal Infection Others Cancer
    Valinomycin is a potassium-specific ionophore, the valinomycin-K + complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K + gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research .
    Valinomycin
  • HY-170483
    Antitumor agent-191

    		HSV HIV Infection Cancer
    Antitumor agent-191 (Compound 7) exhibits antiviral activity against HSV-1 and HIV with EC50 of 0.03 μM and 0.81 μM. Antitumor agent-191 exhibits potential antitumor efficacy, that inhibits cancer cell HepG2, WI-38, Vero and MCF-7, with IC50s of 19.6, 39.3, 18.3 and 28 μM, respectively .
    Antitumor agent-191
  • HY-124662
    IHVR-19029

    		Flavivirus Dengue Virus Glycosidase Infection
    IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy .
    IHVR-19029
  • HY-131944
    S-Acetylglutathione

    		Apoptosis HSV Infection Cancer
    S-Acetylglutathione is a derivative of Glutathione (HY-D0187). S-Acetylglutathione is stable in blood, and can be converted to glutathione by intracellular thioesterases. S-Acetylglutathione restores the intracellular glutathione content in glutathione synthetase deficient fibroblasts. S-Acetylglutathione exhibits antiviral efficacy in HSV-1 infected model through inhibition of viral replication. S-Acetylglutathione induces apoptosis in cancer cells MOLT4 and UKF-NB-3 .
    S-Acetylglutathione
  • HY-159961
    SARS-CoV-2 Mpro-IN-34

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 Mpro-IN-34 (Compound 26) is an inhibitor for SARS-CoV-2 Mpro with an IC50 of 6 nM. SARS-CoV-2 Mpro-IN-34 exhibits inhibitory efficacy against OC43 Mpro with an IC50 of 33 nM. SARS-CoV-2 Mpro-IN-34 exhibits antiviral activity in SARS-CoV-2 infected Vero E6 cell with an EC50 of 0.103 μM .
    SARS-CoV-2 Mpro-IN-34
  • HY-135646
    Eleutheroside B1

    		Influenza Virus Infection Inflammation/Immunology
    Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human influenza virus efficacy, with an IC50 value of 64-125 µg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Eleutheroside B1 inhibits the mRNA expression of several chemokine genes and the influenza nucleoprotein (NP) gene, and exhibits low cytotoxicity. Antiviral and anti-inflammatory activities .
    Eleutheroside B1
  • HY-162719
    RH12

    		SARS-CoV Infection
    RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC50 is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC50 is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC50 of 17.5 nM .
    RH12
  • HY-W014109
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione

    (E)-5-(2-Bromovinyl)uracil; BVU

    		 DNA/RNA Synthesis Infection
    (E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione
  • HY-162720
    NNRT-IN-4

    		HIV Potassium Channel Reverse Transcriptase Infection
    NNRT-IN-4 (Compound 10p) is an inhibitor for non-nucleoside reverse transcriptase (NNRT) with an IC50 of 0.713 µM for HIV-1 RT. NNRT-IN-4 exhibits antiviral efficacy, inhibits HIV-1 wildtype and mutant strains with EC50 of 6-63 nM. NNRT-IN-4 exhibits a slight inhibitory activities against hERG (IC50=25.9 µM) and CYP enzymes (IC50>50 µM). NNRT-IN-4 exhibits good tolerability and safety in mice (2 g/kg) .
    NNRT-IN-4
  • HY-164682
    AMD 3329 octahydrobromide

    		HIV CXCR Infection
    AMD 3329 octahydrobromide is a potent and selective anti-HIV-1 and HIV-2 compound with activity to inhibit viral replication. AMD 3329 blocks viral invasion by binding to the chemokine receptor CXCR4. AMD 3329 exhibits EC50 values as low as 0.8 and 1.6 nM when inhibiting HIV-1 and HIV-2 replication, showing better antiviral efficacy than AMD3100. AMD 3329 significantly inhibits the binding of specific CXCR4 monoclonal antibodies and the Ca(2+) flux induced by SDF-1alpha. AMD 3329 is also able to effectively interfere with virus-induced syncytium formation, with an EC50 value of 12 nM .
    AMD 3329 octahydrobromide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: